Replies to post #41824 on OncoSec Medical Inc (ONCSQ)

[Waitforit53]

Staccani, I think you need to read this regarding your concerns about stage IV, subcutaneous tumors otherwise thought of a soft tissue tumors:

The OncoSec GENESIS™ research generator was developed specifically for gene electro-transfer. It features customizable electroporation parameters for construct-specific optimization of expression, and it is the only in vivo electroporation device enabled with TRACE™ Technology (Tissue-Based, Real-Time Adaptive Control Electroporation.) TRACE™ technology incorporates an electrochemical tissue-sensing control system to automatically adjust pulse width and treatment duration in real time during the electroporation procedure. This feature enables tissue- and therapeutic-specific delivery optimization, maximizing uptake of the therapeutic while reducing unnecessary cell ablation or damage. In research models, GENESIS™ with TRACE™ has yielded higher and more consistent in vivo protein expression versus fixed-parameter electroporation, even in heterogeneous tissues.

Potential advantages of using GENESIS™ with TRACE™ for the objectives of animal immunization include cost savings versus recombinant protein administration, a shortened pre-immunization timeline relative to recombinant protein production, and display of the immunizing antigen in its native conformation. The latter benefit may be particularly relevant for certain therapeutic indications, including immuno-oncology, in which many key targets require functional agonism and/or structurally-complex therapeutic modalities such as multimeric forms. To date, OncoSec has generated multiple high-titer antibody libraries against immuno-therapeutic targets.

The OncoSec Technology Access Program makes OncoSec's electroporation technologies available to collaborators for preclinical research. Devices are available for intratumoral, intradermal, and intramuscular delivery

[hschlauch]

In the case of advanced metastatic melanoma with visceral lesions, you won't need to electroporate the visceral lesions directly if there is an accessible cutaneous lesion. The point of Oncosec's electoroporation platform is to drive a systemic immune response. Once you drive that immune response, the activated T-cells will target for destruction those tumor cells that carry matching antigens; this is how the abscopal effect works. Because the visceral tumors carry the same "fingerprints" as the electroporated tumor, they too will be targeted once the T cells become activated with the tumor matching neoantigens.

For cancers that don't have cutaneous lesions, Oncosec has developed technology that supposedly works with any tissue condition and optimizes protein expression. Oncosec has reportedly been able to successfully express over fifty different proteins intratumorally in preclinical models using this new technology.